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INTRODUCTION
A large number of studies are currently
focused on diagnosis, prevention, and
treatment of complex disorders. Animal
studies are generally utilized as basic mod-
els for in-vivo studies and support sub-
sequent clinical trials. Although animal
models have so far been fruitful in under-
standing the mechanism of several dis-
eases and testing the likely prevention and
treatment strategies; some of them do not
appropriately mimic complex disorders.
There is an emerging need for developing
new models for chronic complex diseases.
Simplifying a complex system is needed
for studying the basis of a complex phe-
nomenon (i.e., Gregor Johann Mendel
studies on Pisum sativum to discover
genetic inheritance roles); however, these
models do not reflect all aspects of a com-
plex system (i.e., epistasis or inter/intra-
allelic gene suppression). When an animal
model is used as the basis of a clinical trial,
it is needed to mimic all complex features
of the patients.
Myocardial infarction (MI) as a lead-
ing cause of mortality and morbidity
worldwide has been extensively studied in
medicine. MI is an acute phenomenon;
however usually it comes after a prolonged
period of atherosclerosis which is accom-
panied by hypoperfusion, hypoxia, and
probably degrees of heart failure. As a mat-
ter of fact acute MI is the final sequence of
the atherosclerosis as a chronic process.
Animal models of MI generally do not
completely mimic MI process. Although
atherosclerosis models are currently avail-
able (Fuster et al., 2012; Getz and Reardon,
2012), usually MI animal models are sur-
gically mimicked by clumping-reperfusion
process (Moon et al., 2003, 2006; Prunier
et al., 2007; Doue et al., 2008; Roubille
et al., 2013b).
Here, as an example, I have tried to
discuss the paradoxical positive results of
animal studies on protective effects of
Erythropoietin (EPO) administration in
reperfused myocardium vs. negative con-
sequences in clinical setting.
It seems that the main fault has been
occurred in MI modeling for EPO treat-
ment at the level of animal experimental
studies, and followed imprecisely with-
out considering the nature of EPO as a
cytokine which is naturally secreted in
human, and the pathophysiologic state of
EPO and EPO receptor in atherosclerotic
patients. This article will emphasize on the
need of developing new models for MI
which mimic its complex character rather
than criticizing studies on cardioprotective
effects of EPO after percutaneous coronary
intervention (PCI) in MI.
ERYTHROPOIETIN
Erythropoietin, traditionally an erythro-
poiesis stimulator cytokine has been
shown to have cell protective properties
principally by reducing apoptosis (Van
Der Meer et al., 2005b; Burger et al., 2006,
2009b). EPO may also enhance neovas-
cularization of ischemic tissue (Van Der
Meer et al., 2005a; Hirata et al., 2006).
Putative cardioprotection of EPO also
has been linked to its anti-inflammatory
properties (Burger et al., 2009a). It was
also reported as one of the protective
factors responsible for hypoxemic pre-
conditioning (Cai et al., 2003). EPO cell
protective effects on myocardial ischemia
were reported in a series of animals as well
as human studies; (Cai et al., 2003; Hirata
et al., 2005, 2006; Van Der Meer et al.,
2005a; Lipsic et al., 2006a,b), however,
the results are quit controversial. Some
studies hypothesized that Erythropoietin
may protect myocardium by direct action
on cardiac myocytes and fibroblasts to
modify survival and ventricular remod-
eling (Parsa et al., 2004). The response of
coronary artery endothelium to EPO stim-
ulation by NO production was suggested
as another probable protective mechanism
of EPO onmyocardium (Teng et al., 2011).
THE ERYTHROPOIETIN PARADOX:
A BRIEF REVIEW ON THE MAIN
PUBLISHED TRIALS
Preliminary animal studies suggest EPO as
an efficient mediator for myocardial pro-
tection (Van DerMeer et al., 2004b; Burger
et al., 2006, 2009b; Westenbrink et al.,
2007a; Lipsic et al., 2008; Prunier et al.,
2009). For example, Moon et al., showed
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that single systemic administration of
EPO dramatically decreased infarct size
and contractile dysfunction 8 weeks after
induction of MI in rats (Moon et al.,
2003).
Following animal experiments, ran-
domized clinical trials (RCT) tried to
study myocardial protective properties of
EPO. Results of HEBE III study in the
Netherlands showed an improvement of
left ventricular ejection fraction (LVEF)
after administration of EPO in a sin-
gle dose (Belonje et al., 2008). However,
in another RCT conducted in France
(EPOMI), Single high-dose EPO after
reperfusion in patients with ST elevation
MI did not decrease infarct size. They
noted that EPO treatment was accompa-
nied by temporary effects on left ventri-
cle size and contractility decreasing the
incidence of microvascular obstruction
(Prunier et al., 2012). No protective effect
was reported in preischemic EPO adminis-
tration in a published study by Kristensen
et al. (2005). According to the results of
a published study by Voors et al., a sin-
gle high dose of EPO after a successful
PCI for a ST elevation MI did not improve
LVEF after 6 weeks. Nevertheless, the
EPO administration was correlated to less
major adverse cardiovascular events and
an admiring clinical safety profile (Voors
et al., 2010). Results of REVEAL study by
Najjar et al on 222 patients with ST ele-
vation MI showed no reduction in infarct
size and surprisingly were linked with
increased rates of adverse cardiovascular
events. On the other hand, an increase
in infarct size among older patients was
also anticipated after subgroup analyses of
their patients (Najjar et al., 2011). Roubille
et al., in a very recent published study con-
cluded that “Early intracoronary admin-
istration of a longer-acting erythropoietin
analog in patients with acute MI at the
time of reperfusion does not significantly
reduce infarct size” (Roubille et al., 2013a).
Finally Meta-Analysis of random-
ized controlled trials revealed that
“Erythropoietin in patients with acute MI
seems to have no clinical benefit for heart
function or reducing infarct size, cardio-
vascular events, and all-cause mortality.
Erythropoietin may not be a choice for
patients with acute MI” (Gao et al., 2012).
Paradoxical negative results of human
studies vs. positive results of animal
studies led to the Erythropoietin para-
dox in reperfused myocardium protection
(Roubille et al., 2013b).
DISCUSSION
The authors of above mentioned pub-
lished clinical trials have tried to eluci-
date their negative findings. However, this
tended to repetition of studies with more
negative results. They have tried to jus-
tify their negative observation as conse-
quence of inclusion criteria (i.e., included
patients were not limited to proximal LAD
occlusion alone), species differences in
EPO response, effective dose, reperfusion-
EPO infusion therapeutic window (time),
and MI sequel evaluation methods (i.e.,
echocardiography vs. cardiac magnetic
resonance imaging, to evaluate infarct
size, ejection fraction, and LV function)
(Prunier et al., 2007, 2012; Huang et al.,
2008; Najjar et al., 2011; Talan et al.,
2012; Roubille et al., 2013a,b). A series
of above mentioned rationalization have
been rejected by later studies (Roubille
et al., 2013a).
Atherosclerotic patients usually suffer
from degrees of hypoxia, tissue hypop-
erfussion (i.e., renal hypoperfusion), and
anemia which may tend to pathophysio-
logically high levels of EPO (Gainer, 1987;
Shimizu et al., 1988; Van Der Meer et al.,
2004a,b, 2008; Westenbrink et al., 2007b).
It has been shown that higher levels of
EPO are accompanied by higher mortal-
ity in a number of patients’ subgroups
(i.e., Patients with heart failure) (Van Der
Meer et al., 2004a). Mortality in these
patients mainly originates from cardiovas-
cular accidents. Higher EPO levels reflect
poor condition of cardiovascular system
and increased likelihood of cardiovascu-
lar accidents. Hence, there is a possibility
that in case of EPO administration, its role
has already been played before MI came to
the stage and degrees of EPO resistance is
predictable in these patients.
On the other hand, as it has been men-
tioned above, in the basic animal exper-
iments MI has been produced with no
previous hypoxia, no hypoperfusion, no
anemia and therefore no high levels of
EPO; (Rekhter et al., 1998) hence, It is
predictable that externally infused EPO
might have protected these animals and
had no similarity with the clinical and bio-
chemical state in EPO resistant patients
(Bamgbola et al., 2009; Bamgbola, 2012;
Chung et al., 2012; Guerrero-Riscos et al.,
2012; Mallick et al., 2012; Okonko et al.,
2013). Additonally, renal function, renal
perfusion, EPO levels and EPO resistance
have not been evaluated in above men-
tioned clinical trials. Additionally there is
likelihood of presence of several unknown
mechanisms that changes EPO sensitiv-
ity and effectiveness in atherosclerotic
patients. We should keep in mind that
“Only a good beginning makes a good
ending”.
CONCLUSION
In conclusion the Erythropoietin paradox
teaches us a very important lesson: let’s
have a second look at the animal mod-
els of MI. When we are studying extrinsic
factors, simple MI models are practical to
some instance, but when we are study-
ing a naturally secreted factor such as a
cytokine, we should note to the chronic
background of acute MI and complex
character of our patients compared to the
simple animal models constructed for a
condition such as MI. The Erythropoietin
paradox certified inappropriate modeling
of MI as a complex phenomenon.
SUGGESTIONS
New animal models should be devel-
oped which mimic chronic complex back-
ground of MI. Combination of currently
available atherosclerosis models with MI
induction techniques could be promising.
Recently new state of the art models such
as Organ on Chip are introduced; (Huh
et al., 2013). Although these new models
are at their infancy, they should be consid-
ered as futuremodels for in-vivo studies on
chronic complex diseases.
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